Pharmaceuticals company Acutaas Chemicals announced Q1FY26 results Revenue from operations for Q1FY26 grew by 17.3% YoY to Rs 2,072 million The gross margin for the quarter improved to 53.2% up 1,117 bps YoY EBITDA for the quarter came at Rs 509 million up 72.4% YoY EBITDA margin for the quarter was at 24.6% as compared to 16.7% in Q1FY25 PAT for the quarter was Rs 440 million up 199.6% as compared to PAT of Rs 147 million in Q1FY25 The PAT margin for the quarter was at 21.2% up 1,292 bps YoY Export for the quarter at 60%; domestic business at 40% Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am happy to share that we’ve had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality. I am happy to announce that we have entered into a joint venture in South Korea which brings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across COMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins.” Result PDF
Pharmaceuticals company Ami Organics announced Q4FY25 results Revenue from operations for Q4FY25 grew by 37.1% YoY to Rs 3,085 million. The gross margin for the quarter improved to 47.3% up 734 bps YoY and 108 bps QoQ. EBITDA for the quarter came at Rs 850 million up 96.8% YoY compared to Rs 432 million in Q4FY24. EBITDA margin for the quarter was at 27.5% as compared to 19.2% in Q4FY24. PAT for the quarter was Rs 627 million up 144.2% as compared to PAT of Rs 257 million in Q4FY24. The PAT margin for the quarter was at 20.3% up 892 bps YoY and 380 bps QoQ. Export for the quarter at 74%; domestic business at 26%. Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenue a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions. As we embark on an exciting new phase of growth, we are embracing a bold, future-focused brand identity that aligns with our vision to lead as a diversified specialty chemicals company, serving next-generation industries with a steadfast commitment to sustainability. To reflect this ambition, we are transitioning from “Ami Organics Limited” to “Acutaas Chemicals Limited”. Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.” Result PDF
Conference Call with Ami Organics Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ami Organics announced Q3FY25 results Revenue from operations for Q3FY25 grew by 65.2% YoY to Rs 2,750 million. The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ. EBITDA for the quarter came at Rs 687 million up 159.0% YoY compared to Rs 265 million in Q3FY24. EBITDA margin for the quarter was at 25.0% as compared to 15.9% in Q3FY24. PAT for the quarter was Rs 454 million up 155.1% as compared to PAT of Rs 178 million in Q3FY24. The PAT margin for the quarter was at 16.5% up 582 bps YoY and 130 bps QoQ. Export for the quarter at 76%; domestic business at 24%. Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am delighted to share that in the first nine months of FY25, we achieved revenue of X698 crore, nearly equalling the revenue from operations of the entire previous financial year. In Q3FY25 alone, we delivered an impressive 65.2% YoY growth, achieving Rs 275 crore in revenue from operations. This performance was driven by a strong ramp-up in our CDMO business and consistent growth in advanced pharmaceutical intermediates. Our pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, solidifying the foundation for sustained long-term growth. Ongoing discussions with innovators and partners remain highly encouraging, and we are confident that the CDMO segment will see exponential growth in the coming years. With improved visibility for Q4, | am pleased to revise our FY25 growth guidance upward from 30% to 35%. This milestone reflects our unwavering commitment to delivering consistent progress, embracing adaptability, and seizing new opportunities that ensure sustainable and impactful growth.” Result PDF